Nonalcoholic steatohepatitis, commonly known as NASH, is reversible in most cases when caught before the liver develops severe scarring. The inflammation and early-stage fibrosis that define the condition can fully resolve with sustained lifestyle changes, medication, or surgery. The critical variable is how far the disease has progressed: mild to moderate fibrosis can be reversed, while advanced cirrhosis cannot be fully undone.
What “Reversal” Actually Means
Doctors define NASH resolution in specific terms visible on a liver biopsy: inflammation drops to absent or mild levels, the characteristic swelling of liver cells (called ballooning) disappears entirely, and existing scarring hasn’t gotten worse. This is the same standard the FDA uses when evaluating whether a new drug works well enough to approve. It’s not just about feeling better or seeing improved blood work. True resolution means the liver tissue itself has healed.
A quick note on terminology: the medical community recently renamed NASH to MASH (metabolic dysfunction-associated steatohepatitis) and NAFLD to MASLD. The name change reflects a better understanding that the disease is driven by metabolic problems like obesity, insulin resistance, and high blood pressure rather than simply being “not caused by alcohol.” You may see either term used, but they refer to the same condition.
Fibrosis Stage Determines Your Ceiling
Liver scarring from NASH is graded on a scale from F0 (no scarring) to F4 (cirrhosis). Where you fall on that scale largely determines how much recovery is possible. Mild to moderate fibrosis (F1 through F3) has clear evidence of reversibility based on repeat biopsies. Patients who successfully address the underlying cause of their liver damage show significantly less scarring when biopsied again months or years later.
Cirrhosis (F4) is a different story. At this stage, the scar tissue has undergone extensive chemical crosslinking, essentially hardening into a permanent structural change. While some improvement is possible, full reversal is not. Researchers describe this as a “point of no return,” though the exact threshold varies between individuals. This is why early detection matters so much. The earlier you intervene, the more reversible the damage.
Weight Loss Is the Most Proven Path
Losing at least 10% of your total body weight is the single most effective non-surgical intervention for reversing NASH. In one study, 63% of patients who hit that threshold saw their fibrosis regress, compared to just 9% of those who lost less. On a statistical level, reaching 10% weight loss made patients roughly eight times more likely to see their scarring improve.
Even smaller amounts of weight loss help with fat buildup specifically. A 12-month trial combining a low-fat, reduced-calorie diet with 90 to 150 minutes per week of moderate exercise found that 50% of people who lost 5% to 7% of body weight resolved their fatty liver disease on imaging. That number jumped to 97% among those who lost 10% or more. The sweet spot for meaningful change in both fat and inflammation appears to be that 7% to 10% range, with fibrosis regression requiring the higher end.
One concern with lifestyle-based approaches is sustainability. Most clinical trials last only 3 to 12 months, and weight regain is common after interventions end. The encouraging news is that patients who went through 6 to 12 months of structured lifestyle change showed lasting benefits up to 5 years later, including less weight regain and sustained improvements in liver fat content compared to those who never underwent the intervention.
What to Eat
The Mediterranean diet has the strongest evidence base for NASH. Its benefits come from a specific combination of fat types, fiber, and anti-inflammatory compounds rather than any single food. The key features include high intake of monounsaturated fats (olive oil, nuts, avocado), omega-3 fatty acids (fatty fish, walnuts), water-soluble fiber from beans, vegetables, fruits, and whole grains, and very low intake of saturated fat and added sugars.
Omega-3 fatty acids help the liver burn fat more efficiently while simultaneously reducing the production of new fat. They also suppress inflammatory signals that drive the progression from simple fatty liver to NASH. The ratio of omega-6 to omega-3 fats matters too. Omega-6 fats, found heavily in vegetable oils like corn and soybean oil, can promote inflammation when consumed in excess relative to omega-3s. Cutting back on fructose from sweetened beverages and processed foods is equally important, as fructose directly fuels fat accumulation in the liver.
Exercise Helps Even Without Weight Loss
This is one of the more surprising findings in NASH research: moderate-to-vigorous aerobic exercise can improve liver inflammation, fat levels, and even early-stage scarring independently of weight loss. In a pilot study of aerobic exercise training over 12 weeks, 58% of participants improved their fibrosis by at least one stage and 67% reduced their liver cell ballooning, despite no significant change in overall body weight. Pooled data show that exercisers were roughly five times more likely to achieve a clinically meaningful reduction in liver fat (30% or more) compared to sedentary controls.
The exact dose needed is still being refined. Most successful trials used 12 to 20 weeks of moderate-to-high intensity aerobic exercise. Current management guidelines recommend at least 150 minutes per week of moderate activity, though the research suggests pushing toward higher intensities may yield better liver-specific results.
Medication and Surgical Options
The first drug specifically approved for NASH targets a thyroid hormone receptor in the liver, helping it metabolize fat more effectively. In its phase 3 trial, about 26% to 30% of patients taking the medication achieved full NASH resolution without worsening fibrosis, compared to roughly 10% on placebo. That means the drug approximately tripled the rate of resolution. It’s currently approved for patients with moderate to advanced fibrosis (F2 or F3) and is taken as a daily pill.
For patients with obesity who haven’t achieved sufficient weight loss through diet and exercise alone, bariatric surgery produces dramatically higher reversal rates. A randomized trial comparing gastric bypass and sleeve gastrectomy to lifestyle modification found that 70% of surgical patients achieved NASH resolution in the per-protocol analysis, versus 19% in the lifestyle-only group. Surgery made resolution roughly 3.6 times more likely. Observational data stretching to five years post-surgery show even higher rates, with 84% achieving NASH resolution and 70% showing fibrosis improvement.
How Long Reversal Takes
Most clinical trials measure outcomes at 12 months, and that appears to be a realistic timeframe for seeing meaningful histological improvement. The key lifestyle trials used 12-month interventions combining reduced-calorie diets (roughly 750 calories below daily needs) with about 200 minutes per week of walking or other low-intensity activity. Imaging-based improvements in liver fat can sometimes appear sooner, within 3 to 6 months, but true resolution of inflammation and scarring on biopsy generally requires at least a year of sustained effort.
Exercise-only interventions have shown histological improvements in as little as 12 weeks, though these studies were small. For medication, the phase 3 trial measured results at 52 weeks. Bariatric surgery tends to produce the fastest changes because the weight loss is both larger and more consistent, with clear benefits documented at one year and continuing to improve through year five.
Tracking Your Progress
Liver biopsy remains the gold standard for confirming NASH resolution, but it’s invasive and not practical for routine monitoring. Most people will track their progress through a combination of blood tests (liver enzymes, markers of inflammation) and a FibroScan, an ultrasound-based device that measures both liver stiffness (a proxy for scarring) and fat content. Declining stiffness values and lower fat scores over time suggest improvement, even without a repeat biopsy. Researchers are also developing non-invasive scoring systems that combine blood markers and imaging data to estimate the probability of NASH resolution, which may eventually reduce the need for biopsies in clinical practice.